The role of lipoprotein (a) in chronic kidney disease

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases

(2016) Florian Kronenberg   CARDIOVASCULAR DRUGS AND THERAPY

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels

(2016) Connor A. Emdin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences

(2016) Nosratola D. Vaziri   KIDNEY INTERNATIONAL

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials

(2016) Amirhosssein Sahebkar et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Live donor study - implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a

(2016) Brian Doucet et al.   NEPHROLOGY

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study

(2016) Barbara Kollerits et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA

(2016) Johannes Kettunen et al.   Nature Communications

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials

(2016)   Lancet Diabetes & Endocrinology

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

(2016) Nathan R. Hill et al.   PLoS One

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance

(2015) Raul D. Santos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus

(2015) J.-S. Yun et al.   DIABETIC MEDICINE

Current therapies for lowering lipoprotein (a)

(2015) Julian C. van Capelleveen et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

(2015) Michael B. Boffa et al.   JOURNAL OF LIPID RESEARCH

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

(2015) Mark J. Graham et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

(2015) George Thanassoulis   JOURNAL OF LIPID RESEARCH

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

(2015) Byambaa Enkhmaa et al.   JOURNAL OF LIPID RESEARCH

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

Relation of Serum Lipids and Lipoproteins with Progression of CKD: The CRIC Study

(2014) M. Rahman et al.   Clinical Journal of the American Society of Nephrology

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

(2014) E. A. Stein et al.   EUROPEAN HEART JOURNAL

Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)

(2014) Peter Willeit et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria

(2014) Jennie Lin et al.   PLoS One

AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy

(2013) Nihar R. Desai et al.   CIRCULATION

Causes and consequences of lipoprotein(a) abnormalities in kidney disease

(2013) Florian Kronenberg   Clinical and Experimental Nephrology

Lipoprotein(a): resurrected by genetics

(2013) F. Kronenberg et al.   JOURNAL OF INTERNAL MEDICINE

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease

(2013) J. C. Hopewell et al.   JOURNAL OF INTERNAL MEDICINE

Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes

(2013) John J. Albers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Notice

(2012)   Kidney International Supplements

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

(2011) Esther Merki et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

(2011) Colin Baigent et al.   LANCET

Chronic kidney disease

(2011) Andrew S Levey et al.   LANCET

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis

(2011) Marion Mafham et al.   PLoS One

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Apolipoprotein(a) Isoforms and the Risk of Vascular Disease

(2010) Sebhat Erqou et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

(2010)   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease

(2010) Hari Krishan Aggarwal et al.   RENAL FAILURE

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE